Mesa Laboratories
Mesa Laboratories' revenue rose 3.4% to $249 million in fiscal 2026. Its operating margin was 7.4%, up from 6.8% a year earlier. Free cash flow was $40 million, down 7.0%. It paid out $4 million in dividends and buybacks, 9% of free cash flow. The diluted share count rose 2.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Mesa Laboratories does
Mesa Laboratories, based in Lakewood, Colorado, makes tools and quality control products for pharmaceutical, healthcare and medical device companies. Customers use them to check that their processes work, for example that sterilization really killed germs. Mesa makes its products in the United States and Europe and sells them through its own sales staff in North America, Europe and Asia Pacific, and through independent distributors worldwide. Its fiscal year ends on March 31.
It reports four segments. Sterilization and Disinfection Control makes biological, chemical and cleaning indicators that show whether sterilization and cleaning worked, mostly single-use items, and offers testing services to dental and drug customers. Biopharmaceutical Development makes automated protein-testing systems and equipment for making peptides, which are short chains of amino acids. Calibration Solutions makes instruments for measuring and calibrating things like gas flow and torque. Clinical Genomics makes genetic analysis instruments and consumables for research labs.
Mesa earns money by selling products, mostly consumables and hardware, and services such as maintenance, calibration and testing. It grows by selling more to current customers and by buying other companies that fit its range. In fiscal 2026 its Clinical Genomics sales fell because of weak demand in China and trade tensions, and Mesa expects that to continue into fiscal 2027.
Its biggest risks, as it describes them
- Weak conditions in the economy and in the markets it serves, including weak demand and trade tensions in China.
- Competition from a wide range of rivals, and industry consolidation or shifts in customer behavior.
- Relying on distributors and other channel partners to reach customers.
- Needing to develop new products on time and win customer acceptance for them.
- Problems getting materials, components and labor on time, and managing growth from acquisitions.
Income statement
From fiscal 2017 to 2026, earnings per share fell 9.3% a year and net income 5.5% a year, as new shares raised the share count by 47% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 49 | 33 | 28 | 27 | 27 |
| Debt incl. finance leases | 169 | 170 | 171 | 71 | 68 |
| Net debt (negative means net cash) | 120 | 137 | 143 | 44 | 41 |
| Net debt to EBITDA | 4.0x | 3.7x | — | 1.1x | 1.0x |
| Debt to equity | 0.4x | 0.4x | 1.2x | 0.5x | 0.4x |
| Interest coverage | 1.2x | 0.7x | −47.8x | 1.4x | 1.7x |
| Current ratio | 2.6x | 2.7x | 2.5x | 0.6x | 1.7x |
| Quick ratio | 2.1x | 1.9x | 1.7x | 0.5x | 1.3x |
Cash flow
Projections
Project Mesa Laboratories' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Mesa Laboratories says to expect
- Fiscal year 2027: revenues and adjusted EBITDA
Issued full-year fiscal 2027 guidance for the first time: revenues of $250,000 to $255,000 and adjusted EBITDA of $66,000 to $68,000
- Third quarter fiscal 2027: revenues
Third quarter revenues are expected to be about flat compared with the prior-year period, mainly because of lower Clinical Genomics revenues.
Insider trades
No officer, director or 10% owner of Mesa Laboratories reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 6 of 9 | 8 of 9 |
| Rule of 40 | 17.9% | 29.1% | 19.3% |
| Altman Z'' | −3.97 | −1.48 | 0.37 |
| Accruals ratio | −53.8% | −11.1% | −8.4% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | 6 of 9 | 8 of 9 |
Compare
Put Mesa Laboratories side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Mesa Laboratories | FY26 | 3.4% | 7.4% | 15.9% | 4.8% | 1.0x | 8 | |
| Cytek Biosciences | FY25 | 0.5% | −20.0% | −4.3% | — | — | — | Compare |
| Maravai LifeSciences | FY25 | −28.3% | −115.9% | −38.1% | −32.0% | — | 2 | Compare |
| Cryoport | FY25 | 12.4% | −20.9% | −14.2% | −23.4% | — | 4 | Compare |
| Ginkgo Bioworks | FY25 | −25.1% | −185.3% | −105.0% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 94 | 96 | 103 | 118 | 134 | 184 | 219 | 216 | 241 | 249 |
| Revenue growth | 10.6% | 2.7% | 7.2% | 14.1% | 13.8% | 37.6% | 18.9% | −1.3% | 11.5% | 3.4% |
| Gross profit | 53 | 55 | 61 | 65 | 87 | 109 | 134 | 133 | 151 | 158 |
| Research and development | 4 | 4 | 4 | 6 | 10 | 16 | 20 | 19 | 20 | 20 |
| Operating income | 16 | 2 | 10 | 8 | 12 | 5 | 3 | −272 | 16 | 18 |
| Net income | 11 | −3 | 8 | 2 | 3 | 2 | 1 | −254 | −2 | 7 |
| Diluted EPS (US$) | 2.91 | −0.79 | 1.86 | 0.41 | 0.64 | 0.35 | 0.17 | −47.20 | −0.36 | 1.21 |
| Diluted shares (millions) | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 |
| Cash flow | ||||||||||
| Cash from operations | 17 | 26 | 31 | 27 | 37 | 39 | 28 | 44 | 47 | 43 |
| Capital expenditure | — | 3 | 1 | 2 | 2 | 4 | 4 | 3 | 4 | 3 |
| Free cash flow | — | 23 | 29 | 25 | 35 | 35 | 23 | 42 | 43 | 40 |
| Dividends paid | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 9 | 16 | 5 | 184 | 0 | 301 | 5 | 79 | 0 | 0 |
| Stock-based compensation | 1 | 2 | 4 | 6 | 9 | 11 | 12 | 12 | 13 | 18 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 6 | 6 | 10 | 81 | 264 | 49 | 33 | 28 | 27 | 27 |
| Debt incl. finance leases | 55 | 46,625 | 23 | — | 146 | 169 | 170 | 171 | 71 | 68 |
| Total assets | 172 | 164 | 157 | 409 | 602 | 707 | 662 | 447 | 433 | 428 |
| Total liabilities | 74 | 65 | 46 | 189 | 195 | 314 | 268 | 301 | 274 | 242 |
| Shareholders' equity | 98 | 99 | 111 | 220 | 406 | 394 | 394 | 145 | 160 | 186 |
| Margins and ratios | ||||||||||
| Gross margin | 56.8% | 56.8% | 59.1% | 55.5% | 65.0% | 59.2% | 61.0% | 61.6% | 62.6% | 63.5% |
| Operating margin | 17.4% | 2.3% | 9.5% | 6.7% | 9.2% | 2.5% | 1.5% | −125.8% | 6.8% | 7.4% |
| Net margin | 11.9% | −3.1% | 7.3% | 1.5% | 2.4% | 1.0% | 0.4% | −117.6% | −0.8% | 2.7% |
| Free cash flow margin | — | 23.8% | 28.4% | 21.7% | 26.2% | 18.9% | 10.7% | 19.2% | 17.7% | 15.9% |
| Rule of 40 (growth + FCF margin) | — | 26.5% | 35.6% | 35.8% | 40.0% | 56.5% | 29.6% | 17.9% | 29.1% | 19.3% |
| Return on capital | 9.4% | 0.0% | 0.0% | — | — | 0.6% | 0.5% | −52.5% | 3.3% | 4.8% |
| Return on equity | 12.3% | −3.0% | 7.1% | 1.1% | 1.1% | 0.5% | 0.2% | −94.4% | −1.3% | 3.9% |
| Return on assets | 6.7% | −1.8% | 4.7% | 0.6% | 0.7% | 0.3% | 0.1% | −45.9% | −0.5% | 1.6% |
| Net debt to EBITDA | 2.0x | 4,000.3x | 0.7x | — | −3.9x | 4.0x | 3.7x | — | 1.1x | 1.0x |